¿Nos visitas desde USA? Entra a tu página Rankia.us.

Foro de Bolsa > Farmas USA

RVNC Nota de Piper: Revance risk/reward attractive into RT002 launch, says

<< Volver al mensaje 'RVNC Nota de Piper: Revance risk/reward attractive into RT002 launch, says'

mugiwara
en respuesta a Investing_saints

Re: Farmas USA

Ver mensaje de Investing_saints

RVNC

Nota de Piper:

Revance risk/reward attractive into RT002 launch, says Piper Jaffray Revance Therapeutics has enough cash to commercialize RT002 in the aesthetics setting following last week's capital raise, Piper Jaffray analyst David Amsellem tells investors in a research note. The company will be launching RT002 into a "consumer-focused, promotion-intensive landscape where it will be up against a well-entrenched competitor," adds the analyst. However, Amsellem continues to believe that the body of data surrounding RT002 in glabellar lines points to the product gaining a "significant foothold." He believes peak sales for RT002 could be well in excess of $1B, making for an attractive risk/reward profile on shares of Revance. The analyst reiterates an Overweight rating on the stock with a $50 price target.

 

  • << Volver al mensaje 'RVNC Nota de Piper: Revance risk/reward attractive into RT002 launch, says'


    Brokers destacados